NIH to Launch New On-Line Repository for Life Sciences Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

BETHESDA, Md-The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/PubMed/.

BETHESDA, Md—The new year will bring a new and controversial source for obtaining access to new scientific studies in the life sciences. In January, the National Institutes of Health (NIH) will launch PubMed Central, a free on-line repository of research reports, found at http://www.ncbi.nlm.nih.gov/pubmed/.

The site will store, organize, and distribute articles, preprints, and screened reports contributed to the repository by scientific journals and “reputable scientific organizations.” It is unclear, however, to what extent peer-reviewed journals will cooperate with the new venture.

PubMed Central is an expanded form of E-biomed, which NIH director Harold E. Varmus, MD, originally proposed in May as a cyberspace library for the biomedical sciences. His idea drew considerable criticism from companies and organizations that publish scientific journals, which feared the free service would cost them subscribers. The plan was also criticized for the use of materials that were not peer reviewed.

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Related Content